ZURICH (Reuters) – Roche Holding is launching with three research institutions a new late-stage clinical trial of its gantenerumab treatment in Alzheimer’s disease, the Swiss drugmaker said on Thursday.
The trial aims to evaluate the potential of gantenerumab to slow disease progression in people with the earliest biological signs of Alzheimer’s disease, before too much permanent neurological damage is done, it said in a statement.
(Reporting by Michael Shields; Editing by Paul Carrel)
Cubs OF Cody Bellinger sidelined by two fractured ribs on his right side
Ex-minor league umpire sues MLB, says he was harassed by female ump, fired for being bisexual man
Mbappe nets twice in win over Lorient but PSG’s title party delayed by Monaco victory
Lindor slugs 2 home runs, Mets end 3-game skid with 8-2 win over Giants
Rebuilding Sharks fire coach David Quinn after 2 disappointing seasons
Meta more than doubles Q1 profit but revenue guidance pulls shares down after-hours
Chicago’s ‘rat hole’ removed after city determines sidewalk with animal impression was damaged
Relatives of those who died waiting for livers at now halted Houston transplant program seek answers
Biden just signed a bill that could ban TikTok. His campaign plans to stay on the app anyway
Rwanda’s Hope Hostel once housed young genocide survivors. Now it’s ready for migrants from Britain
Relatives of those who died waiting for livers at now halted Houston transplant program seek answers
Jill Biden launches bike ride for wounded service members, stresses need to support vets
Gov. Gavin Newsom wants to let Arizona doctors provide abortions in California
More cows are being tested and tracked for bird flu. Here’s what that means
